Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Fc Protein and Glycoengineered Antibodies Market 2016-2021 & 2026 - The Concept of Engineered Antibodies Is Being Widely Used for Development for Biobetters/Biosimilars - Research and Markets

      This image opens in the lightbox

      News provided by

      Research and Markets

      08 Jun, 2016, 19:10 GMT

      Share this article

      Share this article


      DUBLIN, June 8, 2016 /PRNewswire/ --

      Research and Markets has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016 - 2026" report to their offering.

      The study provides a detailed market forecast and opportunity analysis for the short-mid term (2016-2021) and long term (2021-2026). The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios.

      As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market.

      This was done by analyzing:

      - The Fc protein and glycoengineered antibody pipeline in terms of phase of development, type of therapy (monotherapy or combination therapy) and target indications.
      - Technologies established by various players for development of engineered antibody therapeutics including the key mechanism involved, licencing activity, advantages and the molecules being developed using the technology.
      - Partnerships that have taken place in the recent past covering technology licensing, product development and commercialization agreements, clinical trial collaborations, product license agreements, acquisitions and other relevant agreements.
      - Inherent threats to growth in the short and long term.
      - The likely adoption of the Fc protein and glycoengineered antibodies by understanding the competition posed by the current treatment plans and the expected growth rate over the coming few years.

      Example Highlights

      - Overall, we have identified nearly 70 products in marketed, clinical and preclinical stages of development; nearly 60% of the pipeline accounts for molecules in clinical development.
      - The market is characterized by the presence of both small and big pharma players. Notable examples of small to mid-sized firms include (in alphabetical order) arGEN-X, Celldex Therapeutics, Clovis Oncology, Five Prime Therapeutics, Genmab, Immune Design, MorphoSys, TG Therapeutics and Zymeworks. The larger companies in the domain include Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Roche/Genentech, Kyowa Hakko Kirin and Merck.
      - Several firms have also developed their proprietary technologies for Fc optimization and glycoengineering monoclonal antibodies. Examples include (in alphabetical order) BioWa with its POTELLIGENT® technology, Glycart with its GlycoMab Technology, Glycotope with its GlycoExpress, ProBioGen with its GlymaxX® technology and Xencor with its XmAb Fc technology.
      - Encouraging clinical results and prospects in multiple disease areas have yielded an intense framework of collaborative and licensing activity in this field. In fact, between 2005 and February 2016, there have been over 80 collaborations in this space.
      - With two approved drugs, the glycoengineered antibodies are likely to emerge as the forerunner in the short term (84% of the market share by 2021). Subsequently, the Fc protein engineered antibodies are likely to garner a higher proportion (55% by 2026); specifically, Atezolizumab (by Roche) and Durvalumab (by AstraZeneca/MedImmune) are expected to be blockbusters.
      - The overall market is anticipated to grow aggressively at a healthy annual growth rate of over 40% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.

      Key Topics Covered:

      1. Preface

      2. Executive Summary

      3. Introduction

      4. Market Overview

      5. Glycoengineered Antibodies Market

      6. Fc Engineered Antibodies Market

      7. Market Forecast And Opportunity Analysis

      8. Technological Platforms For Developing Engineered Antibodies

      9. Recent Developments

      10. Swot Analysis

      11. Conclusion

      12. Interview Transcripts

      13. Appendix 1: Tabulated Data

      14. Appendix 2: List Of Companies And Organizations

      - AACR
      - AbbVie
      - ABN AMRO Capital
      - Abramson Cancer Center of the University of Pennsylvania
      - Advaxis
      - Agensys
      - Alexion Pharmaceuticals
      - Amgen
      - Applied Molecular Evolution
      - Arana Therapeutics
      - Archimedes Pharma
      - arGEN-X
      - AstraZeneca
      - Avon Breast Cancer Foundation
      - Bayer Healthcare
      - Berlin-Chemie (Menarini Group)
      - Biogen Idec
      - BioMedinvest
      - BioWa
      - Boehringer Ingelheim
      - Bristol-Myers Squibb
      - Cambridge Antibody Technology
      - Cancer Research Institute
      - Cantargia
      - Celgene
      - Celldex Therapeutics
      - Cellective Therapeutics
      - Centocor Research and Development
      - Chugai Pharmaceutical
      - Clinical Cancer Research
      - Columbia University Medical Center
      - Committee for Medicinal Products for Human Use
      - CSL Limited
      - CTI BioPharma
      - Cure Brain Cancer Foundation
      - Daiichi Sankyo
      - Dana-Farber Cancer Institute
      - Deutsche Venture Capital
      - Eisai
      - Eli Lilly
      - Eureka Therapeutics
      - European Cancer Congress
      - European Hematology Association
      - Five Prime Therapeutics
      - Fondazione Italiana Linfomi ONLUS
      - Fountain BioPharma
      - Fredrick Manufacturing Center
      - GamaMabs Pharma
      - Genentech
      - Genitourinary Cancers Symposium of the American Society of Clinical Oncology
      - Genzyme
      - German Breast Group
      - German CLL Study Group
      - Gilde Investment Management
      - GlaxoSmithKline
      - Global Life Science Ventures
      - GlycArt Biotechnology
      - Glycode
      - GlycoFi
      - Glycotope Biotechnology
      - Green Cross
      - Greenovation Biotech
      - GSK
      - GTC Biotherapeutics
      - Hoosier Cancer Research Network
      - Human Genome Sciences
      - Ildong Pharmaceutical
      - ImmunoCellular Therapeutics
      - Immunocore
      - Incyte Corporation
      - Inhibrx
      - Institute of Cancer Research, United Kingdom
      - Italian Network for Tumor Biotherapy Foundation
      - Janssen Pharmaceuticals (Johnson & Johnson)
      - Johannes Gutenberg University Mainz
      - Juno Therapeutics
      - Kairos Therapeutics
      - KaloBios Pharmaceuticals
      - King Faisal Specialist Hospital & Research Center
      - Kolltan
      - Kyowa Hakko Kirin
      - Kyowa Hakko Kogyo
      - LFB Biotechnologies
      - Lonza
      - Ludwig Institute for Cancer Research
      - M.D. Anderson Cancer Center
      - MacroGenics
      - MedImmune
      - Memorial Sloan Kettering Cancer Center
      - Menarini
      - Mentrik Biotech
      - Merck
      - Merus
      - Mirati Therapeutics
      - MorphoSys
      - Nantes University Hospital
      - Naomi Berrie Diabetes Center
      - National Cancer Institute
      - National Institute of Allergy and Infectious Diseases
      - NCIC Clinical Trials Group
      - NEMOD Biotherapeutics
      - Neovii Biotech
      - National Institutes of Health
      - NKT Therapeutics
      - NorthWestern University
      - Novartis
      - Novo Nordisk
      - OncoTherapy Science
      - Ono Pharmaceutical
      - Orpegen Pharma
      - Otsuka Pharmaceutical
      - Oxford BioTherapeutics
      - Parexel
      - Peregrine Pharmaceuticals
      - Pfizer
      - Pharmaceuticals and Medical Devices Agency
      - Pharmacyclics
      - PRA Health Sciences
      - PrECOG
      - ProBioGen
      - ProStrakan
      - Queen Mary University of London
      - Quester Capital Management
      - Raven Biotechnologies
      - Regeneron
      - Roche
      - Sanofi
      - Seattle Genetics
      - Servier
      - Sidney Kimmel Comprehensive Cancer Center
      - Sorrento Therapeutics
      - Spectrum Pharmaceuticals
      - Swiss Federal Institute of Technology
      - Synimmune
      - Synthon
      - Takeda Pharmaceuticals
      - Teva Pharmaceuticals
      - TG Therapeutics
      - Tiziana Life Sciences
      - Tizona Therapeutics
      - Tolerance Therapeutics
      - UCB Pharma
      - United Therapeutics
      - University of Bern
      - University of California, San Diego
      - Ventana Medical Systems
      - VentiRx Pharmaceuticals
      - Xencor
      - Zymeworks

      For more information visit http://www.researchandmarkets.com/research/5d66nv/fc_protein_and

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      press@researchandmarkets.com

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.